NCT05028127View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 4, 2016

Primary Completion Date

June 17, 2016

Study Completion Date

June 17, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

Bimekizumab

Subjects will be receiving bimekizumab at pre-specified time-points.

Trial Locations (1)

Unknown

Harrow

All Listed Sponsors
lead

UCB Celltech

INDUSTRY

NCT05028127 - A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects | Biotech Hunter | Biotech Hunter